Novo Nordisk launches weekly insulin shot Awiqli in India
Novo Nordisk has launched Awiqli, a once-weekly basal insulin injection, in India to treat type 1 and type 2 diabetes. The drug aims to improve patient compliance by reducing the frequency of injections from daily to weekly.
Why it matters
With over 100 million people living with diabetes in India, innovations that simplify treatment regimens can significantly improve public health outcomes.
Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in India on Thursday (July 9, 2026), aiming to compete with daily-dose options on the market.
The report focuses on product launch details, pricing, and market statistics without taking a stance on the company or the drug.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in